From bispecific engineering to clinically relevant data sourcing, evolving antibody technologies advance oncology therapeutics.
PRTA announced that BMS communicated that the FDA granted Fast Track Designation to BMS-986446, an anti-tau antibody in P2 for Alzheimer's disease.
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of diseaseFast Track Designation recognizes the potential of ...
Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.
Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:58 PM EDTCompany ParticipantsMatthew Gline - ...
Seeing the global biopharmaceutical company Creative Biolabs grow its portfolio of antibody engineering has marked a ...
Researchers have discovered how unstructured segments of surface proteins regulate the biological function of a cell. Their ...
Researchers at Leipzig University and Martin Luther University Halle-Wittenberg have investigated a previously unknown ...
JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy ...
Universitätsmedizin Berlin have discovered a key mechanism for appetite and weight control. It helps the brain to regulate feelings of hunger.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback